|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 516.20 DKK | -0.58% |
|
+5.27% | -17.30% |
| Jun. 13 | Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial | RE |
| Jun. 13 | Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing… |  |
| Capitalization | 2,291B 355B 307B 288B 261B 482B 30,589B 546B 3,371B 1,312B 14,003B 1,334B 1,305B 51,156B | P/E ratio 2025 * |
19.6x | P/E ratio 2026 * | 16.4x |
|---|---|---|---|---|---|
| Enterprise value | 2,357B 366B 316B 297B 269B 496B 31,470B 561B 3,468B 1,349B 14,407B 1,372B 1,342B 52,628B | EV / Sales 2025 * |
7.05x | EV / Sales 2026 * | 6.02x |
| Free-Float |
70.25% | Yield 2025 * |
2.56% | Yield 2026 * | 3.01% |
More valuation ratios
* Estimated data
More news
Last Transcript: Novo Nordisk A/S
More recommendations
More press releases
More news
| 1 day | -0.58% | ||
| 1 week | +5.27% | ||
| Current month | +13.79% | ||
| 1 month | +19.26% | ||
| 3 months | -2.64% | ||
| 6 months | -31.54% | ||
| Current year | -17.30% |
| 1 week | 495.3 |  | 533.4 |
| 1 month | 414.35 | | 533.4 |
| Current year | 380 | | 675.2 |
| 1 year | 380 | | 1,033.2 |
| 3 years | 365.3 | | 1,033.2 |
| 5 years | 200.1 | | 1,033.2 |
| 10 years | 109.1 | | 1,033.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 59 | 2016-12-31 | |
| Director of Finance/CFO | 54 | 2018-02-14 | |
Marcus Schindler
CTO | Chief Tech/Sci/R&D Officer | 58 | 2021-02-28 |
| Director | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 64 | 2015-03-18 |
Kasim Kutay
BRD | Director/Board Member | 60 | 2017-03-22 |
Helge Lund
CHM | Chairman | 62 | 2018-03-21 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 21.31% | 200 M€ | -1.07% | - | |
| 10.45% | 4 M€ | +20.79% | - | |
| 5.4% | 21 M€ | +0.03% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.58% | +5.27% | -47.91% | +36.67% | 355B | ||
| +0.90% | +6.43% | -6.73% | +181.77% | 736B | ||
| +0.28% | +1.34% | +7.94% | -6.59% | 378B | ||
| -0.70% | +0.66% | +13.34% | +38.85% | 338B | ||
| -1.06% | +0.56% | +8.93% | -11.79% | 266B | ||
| -0.93% | +0.08% | +2.26% | +20.37% | 235B | ||
| -0.40% | +1.89% | -12.18% | +12.68% | 232B | ||
| -0.13% | +3.47% | -36.89% | -3.30% | 205B | ||
| -0.70% | +1.68% | -1.14% | +25.25% | 159B | ||
| -1.21% | +5.10% | -10.86% | -48.79% | 140B | ||
| Average | -0.45% | +2.94% | -8.32% | +24.51% | 304.24B | |
| Weighted average by Cap. | -0.19% | +3.35% | -7.77% | +52.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 334B 51.84B 44.85B 42.08B 38.13B 70.4B 4,463B 79.63B 492B 191B 2,043B 195B 190B 7,464B | 385B 59.66B 51.61B 48.43B 43.89B 81.03B 5,137B 91.65B 566B 220B 2,352B 224B 219B 8,591B |
| Net income | 117B 18.17B 15.72B 14.75B 13.36B 24.67B 1,564B 27.91B 172B 67.07B 716B 68.19B 66.72B 2,616B | 140B 21.65B 18.73B 17.57B 15.92B 29.4B 1,864B 33.25B 205B 79.91B 853B 81.25B 79.5B 3,117B |
| Net Debt | 65.98B 10.23B 8.85B 8.3B 7.53B 13.89B 881B 15.71B 97.06B 37.77B 403B 38.4B 37.57B 1,473B | 23.47B 3.64B 3.15B 2.95B 2.68B 4.94B 313B 5.59B 34.53B 13.43B 143B 13.66B 13.36B 524B |
More financial data
* Estimated data
Employees
77,406
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-13 | 516.20 kr | -0.58% | 4,576,920 |
| 25-06-12 | 519.20 kr | +0.48% | 3,287,498 |
| 25-06-11 | 516.70 kr | -0.60% | 4,653,954 |
| 25-06-10 | 519.80 kr | +6.01% | 7,848,362 |
Delayed Quote Nasdaq Copenhagen, June 13, 2025 at 11:20 am EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
516.20DKK
Average target price
678.82DKK
Spread / Average Target
+31.50%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NOVO B Stock
Select your edition
All financial news and data tailored to specific country editions
